Novartis Set 'Responsible' Price For Kymriah, Express Scripts Says
Executive Summary
Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.
You may also be interested in...
PBM Controls Coming To Medical Benefit Drugs? Express Scripts Acquisition Offers Platform
Express Scripts' plan to purchase medical benefits management company eviCore may give the PBM an opportunity to bring new pricing pressures to the medical benefit drug space.
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.